XML 43 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenues (Tables)
12 Months Ended
Dec. 29, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Revenues consisted of the following (in thousands):
 Year Ended December 31,
 202320222021
Product revenues:
Gross product revenues
$2,272,533 $1,951,169 $1,452,913 
Discounts and allowances
(643,654)(549,926)(375,657)
Net product revenues1,628,879 1,401,243 1,077,256 
Collaboration revenues:
License revenues
178,635 162,056 249,956 
Collaboration services revenues
22,694 47,763 107,758 
Total collaboration revenues201,329 209,819 357,714 
Total revenues$1,830,208 $1,611,062 $1,434,970 
Net product revenues by product were as follows (in thousands):
Year Ended December 31,
202320222021
CABOMETYX
$1,614,942 $1,375,909 $1,054,050 
COMETRIQ
13,937 25,334 23,206 
Net product revenues
$1,628,879 $1,401,243 $1,077,256 
Schedule of Concentration Risks
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
 
Year Ended December 31,
 
202320222021
Affiliates of AmerisourceBergen Corporation17 %18 %14 %
Affiliates of McKesson Corporation17 %17 %14 %
Affiliates of CVS Health Corporation17 %17 %14 %
Accredo Health, Incorporated12 %10 %%
Affiliates of Optum Specialty Pharmacy10 %10 %%
Ipsen Pharma SAS%10 %21 %
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
 
December 31,
 
20232022
Affiliates of McKesson Corporation21 %22 %
Affiliates of CVS Health Corporation20 %18 %
Ipsen Pharma SAS19 %20 %
Affiliates of AmerisourceBergen Corporation17 %18 %
Cardinal Health, Inc.11 %11 %
Schedule of Revenues Disaggregated by Geographic Region
Total revenues by geographic region were as follows (in thousands):
Year Ended December 31,
202320222021
U.S.
$1,645,749 $1,413,743 $1,089,396 
Europe
144,969 168,592 302,073 
Japan
39,490 28,727 43,501 
Total revenues
$1,830,208 $1,611,062 $1,434,970 
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances
The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
Chargebacks, Discounts for Prompt Payment and Other
Other Customer Credits/Fees and Co-pay Assistance
Rebates
Total
Balance at December 31, 2021
$14,625 $8,875 $24,825 $48,325 
Provision related to sales made in:
Current period355,865 50,312 143,516 549,693 
Prior periods611 (169)(209)233 
Payments and customer credits issued(344,220)(44,094)(132,706)(521,020)
Balance at December 31, 2022
26,881 14,924 35,426 77,231 
Provision related to sales made in:
Current period419,975 56,349 170,788 647,112 
Prior periods295 (1,222)(2,531)(3,458)
Payments and customer credits issued(421,930)(50,330)(163,785)(636,045)
Balance at December 31, 2023
$25,221 $19,721 $39,898 $84,840 
Schedule of Other Assets and Other Liabilities
Contract assets and liabilities were as follows (in thousands):
 
December 31,
 
20232022
Contract assets(1)
$1,321 $1,659 
Contract liabilities:
Current portion(2)
$5,406 $7,488 
Long-term portion(3)
5,524 6,582 
Total contract liabilities$10,930 $14,070 
____________________
(1)    Presented in other long-term assets in the accompanying Consolidated Balance Sheets.
(2)    Presented in other current liabilities in the accompanying Consolidated Balance Sheets.
(3)    Presented in other long-term liabilities in the accompanying Consolidated Balance Sheets.